Evaluation of Dentin Hypersensitivity Using Glass Ionomer Cements

Federal University of Pelotas

Status and phase: Completed; Phase 3; Phase 2

Conditions: Dentin Hypersensitivity

Treatments: Drug: Resin-modified glass ionomer cement Clinpro XT; Drug: Glass Ionomer cement Vidrion R

Study type: Interventional

Funder types: Other

Identifiers

NCT02378129

UFPel

Details and patient eligibility

About

The aim of this randomized, double-blind, split-mouth clinical trial is to evaluate and compare the desensitizing efficacies of the resin-modified glass ionomer cement ClinproTM XT (3M ESPE, Minnesota, USA) and the conventional glass ionomer cement Vidrion R (SS White, Gloucester, UK) at 2-year follow-up.

Full description

Subjects will require to have at least two teeth in different hemiarchs with dentin hypersensitivity. Teeth will be randomized into 2 groups, receiving either Clinpro XT or the conventional glass ionomer cement Vidrion R. Prior to the desensitizing treatment (baseline), painful symptoms will be assessed by tactile and air blast tests using the Visual Analogue Scale (VAS). Treatment evaluations will be conducted up to 2-year post-treatment.

Enrollment: 20 patients

Sex: All

Ages: 28 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male and female subjects between 18 and 70 years old
• At least 2 teeth with dentin hypersensitivity in two different hemiarchs
• Dental elements with hypersensitivity without any pulp alteration
• People who are not taking any medication and women who are not pregnant
• Patients without eating disorders or very acidic diets.

Exclusion criteria

• Teeth with hypersensitivity that presented extensive or unsatisfactory restorations, fractures, periodontal alterations, caries lesions, orthodontic brackets, endodontic treatments, pulp alterations.
• Subjects who received any desensitizing therapy during the last 3 months
• Subjects being under analgesics/anti-inflammatory drugs at the time of the study
• Teeth with hypersensitivity and non-carious cervical lesions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

20 participants in 2 patient groups

Clinpro XT (3M ESPE, Minnesota, USA)

Experimental group

Description:

Resin-modified glass ionomer cement

Treatment:

Drug: Resin-modified glass ionomer cement Clinpro XT

Vidrion R (SS White, Gloucester, UK)

Active Comparator group

Description:

Conventional glass ionomer cement

Treatment:

Drug: Glass Ionomer cement Vidrion R